ATA risk staging (TNM) | Description | Body of evidence suggests RAI improves disease specific survival? | Body of evidence suggests RAI improves disease free survival? | Postsurgical RAI indicated? |
| Tumor size ≤1 cm (uni- or multifocal) | No | No | No |
| Tumor size >1 to 4 cm | No | Conflicting observational data | Not routine* — May be considered for patients with aggressive histology or vascular invasion (ATA intermediate risk). |
| Tumor size >4 cm | Conflicting data | Conflicting observational data | Consider* — Need to consider presence of other adverse features. Advancing age may favor RAI use in some cases, but specific age and tumor size cutoffs subject to some uncertainty.¶ |
| Microscopic ETE, any tumor size | No | Conflicting observational data | Consider* — Generally favored based on risk of recurrent disease. Smaller tumors with microscopic ETE may not require RAI. |
| Central compartment neck lymph node metastases | No, except possibly in subgroup of patients ≥45 years of age (NTCTCSG Stage III) | Conflicting observational data | Consider* — Generally favored, due to somewhat higher risk of persistent or recurrent disease, especially with increasing number of large (>2 to 3 cm) or clinically evident lymph nodes or presence of extranodal extension. Advancing age may also favor RAI use.¶ However, there is insufficient data to mandate RAI use in patients with few (<5) microscopic nodal metastases in central compartment in absence of other adverse features. |
| Lateral neck or mediastinal lymph node metastases | No, except possibly in subgroup of patients ≥45 years of age | Conflicting observational data | Consider* — Generally favored, due to higher risk of persistent or recurrent disease, especially with increasing number of macroscopic or clinically evident lymph nodes or presence of extranodal extension. Advancing age may also favor RAI use.¶ |
| Any size, gross ETE | Yes, observational data | Yes, observational data | Yes |
| Distant metastases | Yes, observational data | Yes, observational data | Yes |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟